Mount Sinai Begins Pilot of Respiratory Disease Management Platform
November 13, 2014 – The Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai is conducting an investigational pilot study of a respiratory disease management platform, developed by Cohero Health, in pediatric asthma patients seen …
Research Funding & Sponsorship Opportunity: Novo Nordisk Diabetes and Obesity Biologics Science Forum
Novo Nordisk is inviting a limited number of leading US academic and medical research institutions to announce this opportunity among those faculty members who could potentially have novel ideas for biologics innovation within diabetes and obesity research. These Awards can be granted …
Mount Sinai Innovation Partners: Open Positions
Mount Sinai Innovation Partners, MSIP, is actively searching for qualified candidates for a number of open positions. To learn more about the opportunities and becoming a part of the Mount Sinai community, click on the links below. Business Development Director Business Development …
SOFT TISSUE SAMPLING TOOL
Dr. Luca Lambertini, co-Director of the Mount Sinai Pregnancy BioBank, and Dr. Men-Jean Lee, Director of Perinatal Research in the Department of Obstetrics, Gynecology and Reproductive Science, have developed a disposable, cylindrically-shaped soft tissue sampling tool that is 1-2 cm in diameter …
EXPANDED CORD BLOOD STEM CELLS FOR USE AS TRANSPLANTATION GRAFTS
Scientists in Drs. Hoffman and Chaurasia’s laboratories have developed a novel approach to substantially expand the numbers of functional Cord blood (CB) hematopoietic stem cells (HSCs) while maintaining true stem cell engraftment capability. Cord blood (CB) cells that express CD34 have extensive …
Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C
July 22, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (otcqb:NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use …
A SET OF 3 URINARY BIOMARKERS AS A PROGNOSTIC/DIAGNOSTIC FOR KIDNEY DISEASE
This technology relates to the use of 3 biomarkers present in urine that can be used to predict kidney disease progression. Briefly, Dr. Böttinger and colleagues have discovered a set of 3 biomarkers that can be used over time to determine the …
THE USE OF CEACAM5 PEPTIDES AS AN IMMUNOTHERAPY FOR CROHN’S DISEASE
Crohn’s Disease (CD) is a chronic relapsing/remitting inflammatory disease of the gastrointestinal tract affecting about 800,000 patients in the US and Europe alone with rising incidence rates. In addition to reduced quality of life for CD patients, the chronic inflammation associated with …
RoSE Scale (Recognition of Smile Excursion)
At the Mount Sinai Medical Center, Drs. Elliott Rose, Peter Taub, Eric Jablonka and Ilya Shnaydman have developed the digitally based RoSE Facial Grading System software program for portable tablets (iPads) and computers to objectively measure smile (facial expression) symmetry in the …
IMPLANTABLE SPINAL RADIATION SHIELD DELIVERABLE BY OPEN OR MINIMALLY INVASIVE SURGERY
The spinal radiation shield is designed to relieve spinal cord compression caused by spinal metastatic disease, as well as allow for higher dose radiotherapy treatments such as brachytherapy and external beam radiation. Dr. Arthur L. Jenkins, III, Neurosurgeon and Head of the Spinal …